SHPH QUANTUM LEAP NEXT GENERATION CANCER RADIATION
Post# of 65
(Total Views: 120)
Posted On: 10/25/2024 1:02:56 PM
SHPH QUANTUM LEAP NEXT GENERATION CANCER RADIATION TREATMENT
https://richardacavalli.wixsite.com/greenplan...n-steroids
Shuttle Pharmaceuticals’ Ropidoxuridine Could Substantially Increase Demand for Improved and Cost-Effective Cancer Radiation Treatments
National Cancer Institute supported clinical trials found iododeoxyuridine (IUdR) is a potent radiation sensitizer that could be a game changer for cancer patients undergoing radiation therapy.
Unfortunately, iododeoxyuridine is troubled by dose-limiting systemic toxicities and the need for prolonged continuous IV infusion that exposes patients to excessive infection risk.
Shuttle developed orally delivered Ropidoxuridine (IPdR) that replaces iododeoxyuridine and solves many problematic issues. Shuttle Pharmaceuticals is beginning Phase 2 clinical trial.
Management is highly experienced. A recent filing shows that the CEO, Dr. Anatoly Dritschilo stepped up with is own personal financing as the company filed an S1 suggesting a new round of finance to fund trials and operations.
Successful clinical trials of Ropidoxuridine have the potential to substantially increase demand for an already large radiation therapy market.
Shuttle Pharmaceuticals Holdings, Inc. has a market cap close to $4 million and a share price of $1.28 as of the close of October 24, 2024.
Radiation therapy is an $8 billion market commonly used to treat cancer, however its’ dosage is limited by the harmful effects it can have on normal healthy cells that are adjacent to the targeted cancerous cells. Limiting the dosage of radiation limits the efficacy of this treatment.
Investment thesis:
A safe drug that would make cancer cells more sensitive and more responsive to radiation therapy would likely be in substantial demand as it could dramatically improve the efficacy and increase the usage of radiation treatment.
Findings in Phase 2 clinical trial of radiation sensitizer iododeoxyuridine
The Phase 2 clinical trial found that iododeoxyuridine (IUdR), is a powerful tool to add to radiation therapy because it makes cancer cells more sensitive to the treatment of radiation.
Iododeoxyuridine (IUdR) is a potent radiosensitizer, however, its clinical utility is limited by dose limiting systemic toxicities and the need for prolonged continuous infusion.
Shuttle Pharmaceutical Holdings, Inc. (SHPH: NASD) Ropidoxuridine is a safer and more effective way to administer radiation therapy
Ropidoxuridine is a prodrug (equivalent) of IUdR that compared to IUdR, is easier to administer and less toxic with a more favorable therapeutic index in preclinical studies.
https://richardacavalli.wixsite.com/greenplan...n-steroids
Shuttle Pharmaceuticals’ Ropidoxuridine Could Substantially Increase Demand for Improved and Cost-Effective Cancer Radiation Treatments
National Cancer Institute supported clinical trials found iododeoxyuridine (IUdR) is a potent radiation sensitizer that could be a game changer for cancer patients undergoing radiation therapy.
Unfortunately, iododeoxyuridine is troubled by dose-limiting systemic toxicities and the need for prolonged continuous IV infusion that exposes patients to excessive infection risk.
Shuttle developed orally delivered Ropidoxuridine (IPdR) that replaces iododeoxyuridine and solves many problematic issues. Shuttle Pharmaceuticals is beginning Phase 2 clinical trial.
Management is highly experienced. A recent filing shows that the CEO, Dr. Anatoly Dritschilo stepped up with is own personal financing as the company filed an S1 suggesting a new round of finance to fund trials and operations.
Successful clinical trials of Ropidoxuridine have the potential to substantially increase demand for an already large radiation therapy market.
Shuttle Pharmaceuticals Holdings, Inc. has a market cap close to $4 million and a share price of $1.28 as of the close of October 24, 2024.
Radiation therapy is an $8 billion market commonly used to treat cancer, however its’ dosage is limited by the harmful effects it can have on normal healthy cells that are adjacent to the targeted cancerous cells. Limiting the dosage of radiation limits the efficacy of this treatment.
Investment thesis:
A safe drug that would make cancer cells more sensitive and more responsive to radiation therapy would likely be in substantial demand as it could dramatically improve the efficacy and increase the usage of radiation treatment.
Findings in Phase 2 clinical trial of radiation sensitizer iododeoxyuridine
The Phase 2 clinical trial found that iododeoxyuridine (IUdR), is a powerful tool to add to radiation therapy because it makes cancer cells more sensitive to the treatment of radiation.
Iododeoxyuridine (IUdR) is a potent radiosensitizer, however, its clinical utility is limited by dose limiting systemic toxicities and the need for prolonged continuous infusion.
Shuttle Pharmaceutical Holdings, Inc. (SHPH: NASD) Ropidoxuridine is a safer and more effective way to administer radiation therapy
Ropidoxuridine is a prodrug (equivalent) of IUdR that compared to IUdR, is easier to administer and less toxic with a more favorable therapeutic index in preclinical studies.
(0)
(0)